Drug Overview

The medical agent known as Fluorescent protease-activated peptide AVB-620 is a highly specialized “Smart Drug” used to assist surgeons during cancer surgery. It is not a traditional medicine designed to kill cancer cells directly. Instead, it is an advanced “Fluorescence-Guided Surgery” (FGS) agent. Doctors use it to make cancer tissue “glow” in real-time while they are operating, helping them distinguish between healthy tissue and a tumor.

Here are the key details about this agent:

Generic Name: Fluorescent protease-activated peptide AVB-620.
US Brand Names: None yet. It is currently an investigational drug.
Drug Class: Diagnostic Imaging Agent / Fluorescence-Guided Surgery (FGS) Agent / Protease-Activated Peptide.
Route of Administration: Intravenous (IV) injection.
FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it has completed advanced clinical trials (Phase 2) and is being reviewed for its accuracy in cancer detection.

What Is It and How Does It Work? (Mechanism of Action)

To understand Fluorescent protease-activated peptide Fluorescent protease-activated peptide AVB-620, imagine a surgeon trying to find a clear path through a forest at night. AVB-620 acts like a chemical flashlight that only turns on when it touches a cancer cell.

The Targeted Chemical Switch

At the molecular level, AVB-620 is a “smart” peptide. It is designed to take advantage of the specific biological environment found in tumors. Here is how it works:

The Molecule Structure: Fluorescent protease-activated peptide AVB-620 consists of a fluorescent marker and a “quencher.” When the molecule is whole, the quencher keeps the fluorescent part dark.
Tumor Enzymes (Proteases): Most solid tumors, especially breast cancer, produce high levels of specific enzymes called Matrix Metalloproteinases (MMP-2 and MMP-9). These enzymes are like biological scissors that cancer uses to break down surrounding tissue so the tumor can grow.
The Chemical Snip: When AVB-620 travels through the bloodstream and enters the tumor area, these MMP enzymes recognize the peptide and “snip” the bond between the fluorescent marker and the quencher.
Glowing Activation: Once snipped, the fluorescent part is no longer “quenched.” It begins to glow brightly when viewed through a special camera during surgery.
Targeted Visualization: Because these enzymes are mostly found in the tumor and not in healthy tissue, only the cancer lights up. This allows the surgeon to see tiny clusters of cancer cells that might have been invisible to the naked eye.

FDA-Approved Clinical Indications

Because AVB-620 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

Breast Cancer Surgery: Used during lumpectomies to ensure that “margins” are clear (meaning no cancer is left behind).
Solid Tumors: Investigated for use in other cancers that produce high levels of MMP enzymes, such as certain head and neck or gastrointestinal cancers.
Lymph Node Mapping: Used to identify if cancer has spread to nearby lymph nodes during an operation.

Non-oncological Uses:

There are currently no non-oncological uses for this agent.

Dosage and Administration Protocols

Because AVB-620 is a diagnostic tool and not a long-term treatment, it is given as a single dose shortly before surgery.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have shown that Fluorescent protease-activated peptide AVB-620 can significantly change the outcome of breast cancer surgeries.

Improving Surgical Accuracy: In Phase 2 clinical trials, researchers found that AVB-620 helped surgeons identify additional cancer tissue that was missed during the initial standard surgery in approximately 10% to 15% of cases.
Reducing Repeat Surgeries: Currently, about 20% of breast cancer patients need a second surgery because the edges of the removed tissue still have cancer cells. Data suggests that using AVB-620 can lower this “re-excision rate” by providing immediate feedback in the operating room.
High Sensitivity: Studies highlight that the drug has a high sensitivity for detecting malignant tissue, with numerical data showing it can distinguish cancer from healthy tissue with over 90% accuracy in certain tumor types.

Safety Profile and Side Effects

Because Fluorescent protease-activated peptide AVB-620 is used in trace amounts for a single procedure, it does not cause the severe side effects associated with chemotherapy.

Common Side Effects (>10%):

Injection Site Reactions: Mild discomfort or redness where the IV was placed.
Skin Discoloration: A temporary, slight change in skin tone or urine color (greenish/blue) as the body filters out the dye.

Serious Adverse Events:

Allergic Reactions (Rare): As with any protein-based injection, there is a very small risk of an allergic reaction (anaphylaxis).
Interference with Pulse Oximetry: Because the dye is fluorescent, it can sometimes interfere with the oxygen-reading clips on the fingers for a short time during surgery.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

Hydration: Patients are encouraged to drink water after surgery to help the kidneys wash the agent out of the system.
Pre-Surgery Screening: Patients are checked for any history of severe allergies to dyes or peptides before the injection.

Research Areas

AVB-620 is at the forefront of Precision Medicine and Targeted Diagnostics. Scientists are currently researching its use in Immunotherapy Tracking. Because the enzymes that activate AVB-620 are also involved in how the immune system responds to a tumor, researchers are looking at whether the “glow” of AVB-620 can tell us if a patient’s immune system is successfully attacking the cancer.

Additionally, in Regenerative Medicine, the technology used in Fluorescent protease-activated peptide AVB-620 is being studied to help identify healthy “scaffolds” for tissue growth. By using markers that only light up in healthy tissue versus scarred tissue, doctors can better plan reconstructive surgeries after a tumor is removed.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

Allergy Testing: A review of any previous reactions to contrast agents used in CT scans or MRIs.
Standard Pre-Op Bloodwork: To ensure the liver and kidneys are functioning well enough to process the agent.

Precautions During Treatment:

Light Sensitivity: While rare, some fluorescent dyes make the skin sensitive to very bright lights for a few hours. Stay indoors and avoid direct sunlight for the first 24 hours.
Medical Identification: Inform your anesthesia team that you have received Fluorescent protease-activated peptide AVB-620, as it can affect oxygen monitoring machines.

“Do’s and Don’ts” List:

DO drink plenty of fluids the day of and the day after your surgery.
DO follow all standard fasting rules for your surgery, even though you are receiving the IV agent.
DON’T be alarmed if your urine looks slightly different in color for 24 hours.
DON’T apply heavy lotions or creams to the surgery site before the procedure.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AVB-620 is an investigational diagnostic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating surgeon regarding diagnosis, surgical options, and eligibility for clinical trials.